To guide the design of immunotherapy strategies for patients with early stage lung tumors, we developed a multiscale immune profiling strategy to map the immune landscape of early lung adenocarcinoma lesions to search for tumor-driven immune changes. Utilizing a barcoding method that allows a simultaneous single-cell analysis of the tumor, noninvolved lung, and blood cells, we provide a detailed immune cell atlas of early lung tumors. We show that stage I lung adenocarcinoma lesions already harbor significantly altered T cell and NK cell compartments. Moreover, we identified changes in tumor-infiltrating myeloid cell (TIM) subsets that likely compromise anti-tumor T cell immunity. Paired single-cell analyses thus offer valuable knowledge of tumor-driven immune changes, providing a powerful tool for the rational design of immune therapies.
INTRODUCTION

Current checkpoint blockade therapies mainly function to rescue T cells from exhaustion or deplete T regulatory cells (Treg).
Studies have begun to dissect the details of T cell function and distribution in advanced tumor lesions to identify novel strategies to further strengthen anti-tumor T cell immunity. Myeloid cells, through their ability to present tumor-associated antigens to T cells and to produce critical T cell differentiation cytokines, have a unique ability to control T cell function at the tumor site. Yet, much less is known about the diversity of the myeloid compartment at the tumor site.
Myeloid cells are a diverse population of immune cells that share the ability to sense and respond to tissue injuries by clearing damaged cells and by promoting the recruitment of immune effector cells that will help restore tissue integrity (Lavin and Merad, 2013; Pham, 2006) . Tumor-infiltrating myeloid cells (TIM) consist of granulocytes and mononuclear phagocytes at varying stages of differentiation and have been shown to contribute to shaping tumor progression and response to treatment (Engblom et al., 2016; Gabrilovich et al., 2012) . Of these, mononuclear phagocytes refer to monocytes, macrophages, and dendritic cells (DC), which, in addition to their innate immune function, share the ability to present tumor-associated antigens to T cells (Ginhoux and Jung, 2014) . Among TIM, DC are the best equipped to drive T cell activation , and a subset of DC, named CD103+ DC, was shown to control local CD8+ T cell activation (Broz et al., 2014; Hildner et al., 2008; Salmon et al., 2016; Sá nchez-Paulete et al., 2016) . Thus, TIM composition appears to control tumor-infiltrating lymphocyte (TIL) composition, activation, and anti-tumor function, and harnessing the TIM compartment may provide a powerful synergistic strategy to potentiate T cell targeting immunotherapies.
Currently, the majority of lung cancer cases are diagnosed at advanced stage. However, this is likely to change, as low-dose A B C
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CT screening programs in populations at risk have shown benefits and are being widely implemented (Aberle et al., 2011; Black et al., 2015) . Five-year survival rates for patients with pathologic stage IA and IB non-small cell lung cancer (NSCLC) are only 83% and 71%, respectively, and these numbers drop to 50% for stage II disease (Goldstraw et al., 2016) with minimal improvement from adjuvant chemotherapy (Pignon et al., 2008) . Preliminary data suggest impressive activity of neoadjuvant immunotherapy in a small number of early stage resectable lung NSCLC lesions treated with anti-PD-1 mAb blockade (Forde et al., 2016) . Although these studies need to be confirmed in a larger cohort, these results are consistent with the notion that immunotherapy agents are most efficient at low tumor burden and in patients naïve of immunomodulatory chemotherapy agents. The design of immunomodulatory strategies for the treatment of NSCLC will, however, tremendously benefit from a detailed understanding of the immune cell landscape that develops specifically in response to tumor cues.
To this end, we developed a multiscale immune profiling strategy to map the immune microenvironment of early lung adenocarcinoma lesions. As tissue cues significantly impact the biology of tissue-resident immune cells and specifically innate cells (Lavin et al., 2014) , we designed a barcoding strategy that allowed the simultaneous single-cell analysis of the distinct immune cell compartments that reside in the tumor site, noninvolved lung tissue (nLung), and blood of each patient to distinguish tumor-driven immune signatures from those caused by normal tissue-imprinting cues. Using mass cytometry by timeof-flight (CyTOF) combined with single-cell transcriptomics and multiplex tissue imaging of the lung tumor, we identify NK and myeloid cell responses that are unique to tumor lesions and absent from nLung or blood from the same patients. We show that these changes are present as early as in stage I tumors and likely compromise anti-tumor immunity. These data suggest that neoadjuvant immunotherapy strategies targeting innate immune cells in early lung adenocarcinoma lesions have the potential to reactivate the TIL microenvironment and transform tumor response to checkpoint blockade.
RESULTS
High-Dimensional Single-Cell Profiling of Lung Tumors
To map the immune microenvironment of lung adenocarcinoma lesions, we designed a clinical multiscale immune profiling study of freshly resected tumors. Patients selected were treatment naïve at the time of surgery. For each patient, we obtained NSCLC tumor tissues including invasive margins, nLung tissue, and blood cells ( Figure 1A ; STAR Methods). Of 32 patients, 28 were diagnosed with lung adenocarcinoma. Patients were representative of the lung adenocarcinoma distribution across age, gender, mutational status, and predominant histological subtype (Table S1 ).
To distinguish tumor-specific immune changes from the lung tissue immune environment, we sought to simultaneously map the immune compartment of the lung tumor lesion, the nLung tissue, and the peripheral blood. To this end, we developed a novel barcoding method that allows a simultaneous analysis of cells from all three sample types. In the first 18-patient cohort, immune cells isolated from the tumor lesion, nLung, and blood were barcoded with anti-CD45 antibodies (Ab) conjugated to unique metal isotopes before samples were pooled. Pooled samples were then stained with two panels of more than 30 antibodies each and analyzed by CyTOF, thus allowing the measurement of single-cell expression on immune cells residing in each tissue type of each patient ( Figure 1A ). The mass cytometry panels were subsequently extended to include cytokine measurement in a cohort of ten additional lung adenocarcinoma patients, as described in the STAR Methods.
T Cells and Mononuclear Phagocytes Dominate the Early Lung Adenocarcinoma Microenvironment
Using viSNE to visualize high-dimensional data in two dimensions while preserving single-cell resolution (Amir et al., 2013) , we analyzed the distribution of the different immune cell lineages that accumulated in lung tumor lesions, nLung, and blood circulation across patients (Table S1 and Data S1). A higher number of immune cells accumulated in the tumor tissues compared to nLung ( Figure S1A ). The tumor-resident immune cell compartment comprised all major immune lineages, and the most abundant were the T lymphocytes and mononuclear phagocytes ( Figures 1B-1D , and S1B). Mononuclear phagocytes and granulocytes were equally represented in tumor lesions compared to nLung. In contrast, T and B lymphocytes were present at a higher frequency in the tumor microenvironment compared to the nLung, whereas the frequency of NK cells was significantly reduced across all lung adenocarcinoma patients examined ( Figures 1C, 1D , and S1C).
We also analyzed the cytokines and chemokines produced in the tumor milieu. Whereas many chemokines and cytokines were expressed at much higher levels in the tumors compared to the blood, similar chemokine levels were often detected in tumors and adjacent nLung, which could potentially reflect the A) Schematic for defining the immune composition of lung tumors. Blood, non-involved lung (nLung), and tumor tissue were collected from patients undergoing surgical resection of primary tumors, processed, barcoded, pooled, and stained with antibodies conjugated to metal isotopes. Mass cytometry (CyTOF) singlecell data was clustered using Phenograph to identify common populations across patients. Artwork printed with the permission of Mount Sinai Health System. (B) viSNE analysis of immune cells from tumor colored by relative expression of CyTOF markers, with populations indicated (top). (C and D) Frequency of immune lineages based on summation of Phenograph metaclusters (STAR Methods; n = 18). Composition of the CD45+ compartment showing average frequencies of major immune lineages for each tissue ( [C] ; n = 18) across patients and bar plots showing frequencies for each patient ( [D] ; *p < 0.05, **p < 0.01, and ***p < 0.001 by paired t-test). Bar plots show mean ± SEM. (E and F) MICSSS for CD3, CD68, and CD20 of immune infiltrate (E) and a tertiary lymphoid structure (TLS; [F] ) at the tumor invasive margin and non-involved lung from representative patients. See also Figure S1 . local diffusion of tumor-produced soluble molecules to the adjacent lung tissue (Figures S1D and S1E). Interestingly, CX3CL1 (fractalkine) was expressed at slightly higher levels in tumors compared to nLung and correlated with the frequency of the mononuclear phagocyte infiltrate ( Figure S1F ). Recent studies have shown that, in addition to cell composition, the spatial distribution of immune cells at the tumor site may affect tumor outcome (Germain et al., 2014) . Using a new tissue-profiling method named ''multiplexed immunohistochemical consecutive staining on a single slide'' (MICSSS) that we recently developed in the laboratory , we assessed the distribution of immune cells in the tumor and nLung sections. Immune cells accumulated mainly in the stroma and invasive margin surrounding the tumor islets as previously described (Salmon et al., 2012; Turley et al., 2015) , although some macrophages and T cells were able to infiltrate into the tumors (Figures 1E and S1I) . We also observed an abundance of mononuclear phagocytes and T cells at the tumor site across patients supporting the CyTOF results ( Figures 1D,  1E , and S1B). Importantly, many patients had tertiary lymphoid structures (TLS), which accumulated near the tumor invasive margin and were absent from nLung ( Figures 1F and S1I ). Tumor lesions enriched in TLS had significantly more T lymphocytes and fewer mononuclear phagocytes as measured by CyTOF at the tumor site ( Figure S1H ).
To further probe the nature of the immune response induced at the tumor site in an unbiased manner, we analyzed the CyTOF data using the Phenograph algorithm to systematically identify common cellular communities across the three tissues and across all patients (Levine et al., 2015) . We first clustered single cells based on shared protein expression across tumor lesions, nLung, and peripheral blood mononuclear cells (PBMCs) within each patient then merged clusters from each patient using a secondary clustering analysis to identify metaclusters common across patients and tissues ( Figure 1A ).
Tumor Lesions Are Enriched in Treg and Non-functional T Cells
Phenograph clustering across tissues and across all patients revealed distinct T lymphoid metaclusters (Figures 2A, 2B , and S2A) that corresponded to known immune cell populations and had a unique distribution across tissue sites (Figures 2C and S2B) .
Paired mass cytometry analysis revealed a distinct composition and phenotype of T cell subsets ( Figures 2C and S2B ). Specifically, Treg were significantly increased in the tumor lesion across all patients even at early stages ( Figure 2C ). Importantly, Treg at the tumor sites expressed high levels of CTLA4, CD39, ICOS, and 41BB compared to other T cells ( Figures 2D and  S2D ). They were also clearly distinguishable from Treg that resided in nLung based on higher expression of Foxp3, CTLA4, PD-1, CD39, ICOS, CD38, and 41BB, whereas CCR4 was decreased ( Figures 2E, S2E , and S2F). In contrast, cytolytic CD8+ T cells were significantly reduced in frequency in the tumor compared to nLung and blood from the same patients ( Figure 2C ). Moreover, total CD8+ T cells present in tumors expressed significantly less granzyme B and IFNg upon stimulation compared to their nLung counterparts ( Figure S2G) . A reduced T-effector/Treg ratio was thus a strong signature of the lung tumor lesion ( Figure S2C) .
Given the success of anti-PD-1 checkpoint blockade in lung cancer patients, we examined the expression of the checkpoint molecule PD-1 on all T cell metaclusters identified across tissues. PD-1 was distinctly expressed on a small subset of CD4+ and CD8+ T cells that were a unique feature of the tumor (Figures 2C and S2H) and at a lower level on Treg at the tumor site ( Figure 2D ). CD8+ T cells accumulate at the tumor site and in TLS, where they preferentially expand (Figures 2F and S2I; Goc et al., 2014; Joshi et al., 2015) , and clonality of the T cell receptor (TCR) repertoire has been associated with TLS density (Zhu et al., 2015) . Consistent with these findings, T cells were significantly increased in TLS-enriched tumors ( Figure S1H ). Moreover, while there was no enrichment in TCR clonality in tumors compared to nLung, the CD8+PD-1+ T cell subset uniquely and significantly correlated with increased TCR clonality at the tumor site but not in nLung ( Figures 2G and S2J ). These results suggest that CD8+ T cells expressing PD-1 are clonally expanded at the tumor site and that this expansion may preferentially occur in TLS-enriched tumor lesions.
Cytolytic NK Cells Are Excluded from Lung Adenocarcinoma Lesions
In addition to measuring adaptive lymphocyte responses to tumors, we also analyzed the distribution of innate lymphocytes and in particular NK cells in lung tumor lesions. Strikingly, NK cells were the least abundant immune cell lineage in lung adenocarcinoma lesions compared to nLung ( Figures 1C and 1D) . Importantly, the NK cell subset expressing CD16 was most dramatically reduced in the tumor compared to nLung ( Figures  3A and S3A ). NK cells that infiltrated the tumor lesion expressed higher CXCR3 levels, a molecule shown to be required for NK infiltration of tumors (Figures 3B and 3C; Wendel et al., 2008) . Moreover, NK cells that remained at the tumor site were less cytolytic, as they expressed lower levels of granzyme B and CD57 as well as less IFNg ( Figures 3C-3E and S3C ). Conversely, since NK cells function to eliminate MHC class-I-deficient cells, we assessed the distribution of MHC class I throughout the tumor cells using MICSSS ( Figure 3F ). Tumor lesions with reduced frequency of MHC class-I-expressing tumor cells had higher numbers of tumor-infiltrating CD16+ NK cells, suggesting that the presence of cytolytic NK cells may have led to MHC class I immuno-editing ( Figures 3G and S3D ).
Deciphering the Diversity of TIM in Lung Adenocarcinoma Lesions
To fully capture the heterogeneity of the TIM compartment, we first performed an unbiased single-cell transcriptomic analysis of non-lymphocyte cells that accumulated in the tumor lesion and in the nLung of a stage I patient using massively parallel single-cell RNA-sequencing (MARS-seq; Figure 4A ; Data S2B; STAR Methods; Jaitin et al., 2014) . Single-cell RNA-seq analysis of TIMenriched cells, using an unbiased expectation-maximization algorithm previously described (STAR Methods; Paul et al., 2015) , revealed several immune cell types distinguished based on characteristic gene expression profiles identified according to highly expressed and differential genes ( Figure 4A ; Table S3 ). Specifically, we identified three distinct clusters expressing high levels of MHC class II molecules, CD1C, CCL22, and CD207 ( Figure 4A , clusters 2-4) and slightly higher BATF3 and CSF2RA expression levels ( Figures 4E and S4A ), which we inferred to be DC. Other clusters were identified as macrophages ( Figure 4A , clusters 5-8) and monocytes (clusters 9-10) based on the differential expression of CD68, MAFB, and CSF1R ( Figures 4E and S4A) . A macrophage cluster comprised predominantly of cells from tumor lesions (cluster 7) was distinct from those comprised predominantly of cells from nLung (clusters 5-6), indicating that tumor-associated macrophages were distinct from their nLungresident macrophage counterparts. To detail the TIM compartment across patients, we systematically defined myeloid cell populations across patients using simultaneous CyTOF analysis of PBMC, nLung, and tumor immune cells. Phenograph clustering of all tissues in all patients confirmed the diversity of myeloid cells in the tumor, and macrophages, DC subsets, and monocytes subsets were identified based on expression of protein markers, including CD68, CSF1-R, CSF2-R, CD11C, CD1C, CD141, and HLA-DR among others ( Figures 4B, 4C , 4E, and S4B). TIM were distinct from their lung and PBMC counterparts ( Figures 4D and S4C ). Indeed, paired CyTOF analysis revealed unique distributions and functions of CD14+ and CD16+ monocyte subsets in the tumor site ( Figures 4D and S4D ). While CD14+ monocytes were robust cytokine producers compared to other mononuclear phagocytes ( Figures 4F, S4E , and S4F), they produced less IL-8 and less IL-1b at the tumor site compared to the nLung (Figures 4G and S4G) . In contrast to the CD14+ monocytes that equally infiltrated tumor and lung tissues, CD16+ monocytes were significantly reduced in tumor tissues and highly correlated with NK cell infiltration at the tumor site ( Figures 4D, S4D , and S3B).
Finally, while tumor lesions were equally enriched in neutrophils and eosinophils compared to nLung, they contained significantly fewer basophils and were strongly depleted of mast cells ( Figure 4D ).
Paired Immune Cell Mapping Reveals a Distinct Macrophage Signature in Lung Adenocarcinoma
Single-cell transcriptomic analysis revealed distinct macrophage clusters that were differentially distributed in the tumor and nLung ( Figure 4A , clusters 5-8). Comparing the macrophage cluster enriched in tumors (cluster 7) to those comprised primarily of nLung cells (clusters 5 and 6) revealed many differentially expressed genes, suggesting that tumor-associated macrophages have a distinct transcriptional signature ( Figure 5B ).
Using paired CyTOF analyses, we found that, while macrophages were not enriched in frequency in the tumor site compared to nLung (Figures 5A and S5A) , tumor macrophages exhibited a distinct signature compared to their lung-resident counterparts across all patients ( Figures 5C and 5D ). CyTOF analysis validated several of single-cell transcriptomics findings, thereby confirming that tumor macrophages expressed higher levels of the immunomodulatory transcription factor PPARg; higher CD64, CD14, and CD11c levels; and lower CD86 and CD206 levels compared to macrophages that resided in nLung ( Figure 5D ).
Single-cell transcriptional analysis identified additional transcripts up-regulated on the tumor macrophage cluster compared to their nLung counterparts (cluster 7), including triggering receptor expressed on myeloid cells-2 (TREM2), tetraspanin CD81, macrophage receptor with collagenous structure (MARCO), and apolipoprotein E (APOE; Figure 5B ). To understand whether this differential transcriptional signature extends to other patients, we stratified 515 lung adenocarcinoma patients from the TCGA database according to the differential transcriptional profile. A significant survival disadvantage was observed in patients Bar plots show mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001 by paired t-test. See also Figure S3 .
with a high ratio of tumor macrophages to lung macrophage gene expression profile ( Figure S5G ), suggesting that the macrophage signature identified in this study may include novel myeloid targets for lung cancer treatment.
Given the clinical success of anti-PD-L1 in lung cancer (Besse et al., 2015; Fehrenbacher et al., 2016) , we examined the distribution of PD-L1 in lung tumor lesions using paired mass cytometry analysis. Strikingly, PD-L1 was most highly expressed on macrophages and mast cells both in tumor and nLung (Figures 5E, S5B, and S5C) . These results are consistent with our data in mice (data not shown) and suggest a potential role for PD-L1 in the physiological regulation of lung-immune homeostasis, which could explain the increased rate of pneumonitis in patients treated with PD-L1 inhibitors (Naidoo et al., 2017; Nishino et al., 2016) . Given the impact of PD-L1+ cells on tumor outcome, we analyzed the spatial distribution of PD-L1+ macrophages and found that they accumulated in tight clusters at the tumor invasive margin (Figures 5E and S5D) and negatively correlated with T cell infiltration in tumor lesions but not in nLung ( Figure S5E ).
Tumor macrophages also spontaneously produced significantly more IL-6 than macrophages in nLung (Figures 5F and S5F). Given the potential role for IL-6 in tumor invasiveness (Chang et al., 2013; Yu et al., 2014) and the negative correlation between the presence of macrophages and T cells at the tumor site, these data emphasize the immunosuppressive role of tissue-resident macrophages in early lung adenocarcinoma lesions.
CD141+ DC Have a Distinct Phenotype and Are Excluded from Lung Tumor Lesions DC excel at antigen presentation and play a key role in the induction of anti-tumor T cell immunity. Single-cell transcriptional analysis of the tumor and nLung revealed the presence of two DC clusters ( Figure 4A , clusters 2 and 4), one of which expressed high CD207, CLEC9A, and XCR1 levels and likely represent CD141+ DC (Dutertre et al., 2014; Haniffa et al., 2013) . We also detected a second DC cluster expressing higher levels of CD1c, CX3CR1 and IRF4, which we inferred to be CD1c+ DC ( Figures 6A, 6B , and S6B). The CD1c+ DC cluster also expressed higher levels of CCL22 and CCL17, ligands for CCR4, a molecule expressed mainly by CD4+ T cells (Yoshie and Matsushima, 2015) , and higher lysozyme transcripts compared to the CD141+ DC ( Figure 6B ). These findings are in line with the increased potency to interact with CD4+ T cells and increased degradative potential of CD1c+ DC, in contrast to CD141+ DC that interact preferentially with CD8+ T cells (Dutertre et al., 2014; Haniffa et al., 2013; Merad et al., 2013) . Lymphotoxin beta (LTB) transcript, encoding a membrane-bound protein important for the formation of secondary lymphoid organs and potentially TLS (Pitzalis et al., 2014) , was highly expressed by DC and at slightly higher levels by the CD141+ DC cluster ( Figure 6E ).
Paired CyTOF analyses identified the presence of two DC subsets at the tumor site across patients. Strikingly, CD141+ DC, but not CD1c+ DC, were significantly reduced in tumors compared to nLung, and the CD1c+ DC/CD141+ DC ratio was thus increased in tumor lesions ( Figures 6C, S6A and S6C) . Importantly, CD1c+ DC expressed a very similar cytokine profile to CD14+ monocytes and produced IL-6, IL-8, and IL-1b cytokines in the tumor and nLung ( Figure S4E ). Using MICSSS, we found that, in lesions infiltrated with TLS, DC localized in TLS and close to T cells ( Figures 6D and S6D ), in line with their role in T cell activation and clonal expansion (Dieu-Nosjean et al., 2008 S6E ). These differences compared to nLung likely work in concert to promote an immunosuppressive microenvironment. As TNM staging is used to determine both prognosis and treatment options, we examined whether the immune contexture of the tumor lesions significantly differed between early stage (stage I) and later stage tumors (stages II and III). With the exception of increased neutrophils and TNFa production in stage II and stage III patients ( Figure 6G ), all immune changes detected in later stage tumor lesions were already present in stage I tumors. The distribution of immune cell subsets including macrophages, monocytes, NK cells, and DC as well as B and T cell subsets did not significantly differ in frequency across stages ( Figures 6F and S6F ). In addition, expression levels of PD-1 and PD-L1 on macrophages and T cells, respectively, were stable across TNM stages ( Figures S6G and S6H ), (D) Bar plots of metacluster frequencies from 18 lung adenocarcinoma patients across tissue (*p < 0.05, **p < 0.01, and ***p < 0.001 by paired t-test). (E and F) Expression of corresponding transcript and protein by MARS-seq and CyTOF, respectively. Normalized transcript expression of MARS-seq clusters (left) and normalized protein expression of select Phenograph metaclusters in the tumor (right) for phenotypic markers ( [E] ; n = 18), and cytokines ( [F] ; n = 10) with corresponding viSNE plots. (G) Bar plot of normalized IL-8 expression by CD14+ monocytes across tissue (n = 10; *p < 0.05, **p < 0.01, and ***p < 0.001 by paired t-test). Bar plots show mean ± SEM. See also Figure S4 . suggesting that immunomodulatory strategies could benefit early stage tumors.
DISCUSSION
Driven by the premise that the myeloid cell compartment and most specifically the tumor-infiltrating antigen-presenting cells critically shape the composition of anti-tumor T cells, the objective of this study was to provide an innate immune cell atlas of early lung adenocarcinoma lesions. Using paired single-cell analyses of the immune cells that reside in the tumor, nLung, and peripheral blood, we distinguished the immune changes driven by the tumor lesion from those driven by the lung tissue, emphasizing the relevance of this type of analysis for the study of the tumor microenvironment. Strikingly, as early as in stage I disease, lung adenocarcinoma lesions had a strongly reduced CD8+ T effector/Treg ratio compared to nLung. This altered T cell ratio resulted from a significant reduction of CD8+ T cells expressing granzyme B and IFNg and also from a significant expansion of CD39
hi Tregs at the tumor site. In line with previous results showing that Foxp3/CD3 ratio is a strong predictor of recurrence in early stage tumors (Suzuki et al., 2013) (Hanna et al., 2015) , and thus, reduced CD16+ monocytes in lung tumors might have contributed to NK cell paucity in tumor lesions. CD14+ monocytes in the tumor produced high levels of the cytokine IL-8, but those in nLung produced even more. IL-8 can promote lung cancer growth and metastasis (Chen et al., 2003; Zhu et al., 2004) , and in smokers, IL-8 expression in non-tumor lung tissue is part of a lung cancer biomarker signature (Spira et al., 2007) . Given the potential role of monocytes in lung metastasis (Qian et al., 2011) , monocytederived IL-8 in nLung may have contributed to tumor cell engraftment. Interestingly, while we identified a drastic increase in cytokine production in the tumor tissue compared to the blood, many cytokines were equally expressed in the tumor and nLung. CX3CL1, however, tended to be expressed at higher levels at the tumor site and significantly correlated with mononuclear phagocytes, particularly CD14+ monocytes in the tumor lesion. CX3CL1 was found to be increased in patients that failed to respond to PD-1 (Herbst et al., 2014) . Therefore, it will be important to further assess CX3CL1 and CD14+ monocytes as biomarkers of treatment response. Tissue-resident DC consist of two main subsets that are transcriptionally and functionally distinct. In mice tissues, these include the CD103+ DC subset, which derives from DC-restricted precursors and excels in the cross-presentation and priming of CD8+ T cells, and the CD11b+ DC subset, which has a higher degradative potential than CD103+ DC and mainly interacts with CD4+ T cells . Human CD141+ DC and CD1c+ DC share similar transcriptional profiles with murine CD103+ DC and CD11b+ DC, respectively, and are thought to represent their human counterparts (Dutertre et al., 2014; Haniffa et al., 2013) .
We and others found that the absence of CD103+ DC abolishes tumor response to checkpoint blockade in experimental tumor models, while expansion and activation of CD103+ DC dramatically increased T cell recruitment to the tumor site and transformed response to checkpoint blockade (Broz et al., 2014; Hildner et al., 2008; Roberts et al., 2016; Salmon et al., 2016; Sá nchez-Paulete et al., 2016) . Here, we found that early lung adenocarcinoma tumors were significantly depleted in CD141+ DC compared to nLung, while CD1c+ DC were slightly increased in tumors, resulting in an increased CD1c+/CD141+ DC ratio at the tumor site.
We also found that tumor CD1c+ DC shared the same innate cytokine profile with monocytes, consistent with the notion that CD1c+ DC likely represent monocyte-derived cells generated upon entry at the tumor site, whereas CD141+ DC are thought to arise from DC-restricted precursors (Dutertre et al., 2014; Haniffa et al., 2013) . Interestingly, DC localized close to T cells in TLS, in line with their potential key role in T cell activation and clonal expansion (Dieu-Nosjean et al., 2008) . DC-derived LT has recently been shown to directly act on high endothelial venules (HEV) to promote lymphocyte homing to peripheral lymph nodes in vivo (Moussion and Girard, 2011) . Our finding that DC and especially the CD141+ DC subset expressed lymphotoxin beta (LTB) transcripts in lung tumor tissues likely reflects that CD141+ DC contribute to TLS formation, potentially through HEV-mediated recruitment of lymphocytes. This hypothesis is consistent with our finding that TLS-enriched tumors have increased T cells, and it strengthens the mechanistic understanding of the positive prognostic value conferred by TLS when identified by DC-LAMP immunostaining (Dieu-Nosjean et al., 2008; Germain et al., 2014; Pitzalis et al., 2014) . Altogether, these results suggest that expansion of intra-tumoral CD141+ DC may provide a key strategy for the induction of potent anti-tumor immunity.
Importantly, while macrophages were not enriched in the tumor lesion compared to nLung, tumor macrophages expressed a unique phenotype compared to macrophages in nLung. In particular, tumor macrophages expressed higher levels of PPARg, a transcription factor known to drive an immunosuppressive program (Reddy, 2008; Ricote et al., 1998) , and lower levels of the co-stimulatory molecule CD86. They also produced higher levels of IL-6, indicating that these tumor macrophages are pro-tumorigenic. CD206, thought to represent a marker of alternatively activated macrophages and tumor macrophages, was expressed at lower or similar levels on tumor macrophages compared to lung macrophages, consistent with recent data showing that CD206 is a marker of lung alveolar macrophages (Desch et al., 2016; Yu et al., 2016) . This emphasizes the importance of paired analyses to distinguish tumor-driven immune changes from normal tissue-imprinting. Single-cell transcriptomic analysis of myeloid cells further extended these results and identified a unique gene signature of tumor macrophages that included, among other genes, TREM2, recently shown to promote chronic lung diseases through inhibition of macrophage apoptosis after acute viral infection . Finally, using multiplex tissue imaging, we identified clusters of PD-L1+ macrophages at the tumor-invasive margin, suggesting their potential contribution to modulating T cell entry in the tumor lesion. Accordingly, increased macrophages correlated with reduced T cells at the tumor site and, in contrast to TLS-enriched tumors, lesions devoid of TLS were mostly enriched in macrophages. Thus, lung tumors enriched in macrophages and reduced in TLS may specifically benefit from immunotherapy strategies to deplete macrophages while expanding DC prior to treatment with checkpoint blockade.
By combining multiplex tissue imaging and paired single-cell analysis of the tumor, nLung, and blood, this study provides a detailed immune cell atlas of early lung adenocarcinoma and identifies, along with specific T cell alterations, innate immune cell changes that are unique to the tumor lesion and absent from nLung. Our identification of significant innate immune cell changes in early stage lung adenocarcinoma lesions suggests that neo-adjuvant or adjuvant immunotherapy strategies tailored to restore innate immune changes might be uniquely poised to shape the tumor T cell microenvironment and transform tumor response to checkpoint blockade.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Specimens Blood, non-involved lung and tumor tissues were obtained from patients undergoing lung resection surgery at the Mount Sinai Medical Center (New York, NY) after obtaining informed consent. All protocols were reviewed and approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai (IRB 08-1236).
Patient Clinical Characteristics
Samples were collected from 32 patients, 28 of whom were diagnosed with adenocarcinoma and thus included in the study (Table  S1 ). The 28 patients consisted of 12 males and 16 females and ranged from ages 47 to 83 years old, with a median of 67 years old.
METHOD DETAILS
Sample Collection From the patients described above, blood was collected intraoperatively into sodium heparin tubes (BD). For solid tissues, care was taken to collect tumor with invasive margin and non-involved lung as distant as possible from the tumor and anatomic abnormalities. Tissue samples were placed in RPMI media (Corning) on ice. For all collected tissue samples, H&E slides were reviewed by a pathologist, and non-involved lung tissue samples with tumor infiltration (2 patients) were excluded from the analysis.
Collection of Histological Sections
Non-involved lung and tumor tissue were briefly washed in PBS. From each sample, two histological sections were carefully cut so as to not disturb tissue architecture. One histological slice was placed in 10% buffered formalin phosphate (Fisher Scientific) for 24 hours and stored in 70% ethanol before being embedded in paraffin. The other slice was placed in OCT (Tissue-Tek) and placed on dry ice before storage at -80 C.
Multiplexed Immunohistochemical Consecutive Staining on a Single Slide
Five mm-thick formalin-fixed paraffin-embedded (FFPE) tissue sections on glass slides were backed at 37 C overnight, deparaffinized in xylene, and rehydrated in decreasing concentrations of ethanol. Then, tissue sections were incubated in retrieval solution (Citrate buffer, pH6) for antigen retrieval at 95 C for 30 minutes. Tissue sections were incubated in 3% hydrogen peroxide and in serum-free protein block solution (Dako, X0909) before adding the primary antibody (CD68, clone KP1, Dako) for 1 hour at room temperature. After signal amplification using biotinylated-secondary antibody and streptavidin-horseradish peroxidase, chromogenic revelation was performed using 3-amino-9-ethylcarbazole (AEC). Slides were counterstained with hematoxylin, mounted with a glycerol-based mounting medium and scanned for digital imaging (Pannoramic 250 Flash III whole-slide scanner, 3DHISTECH). Then the same slides were successively stained as described . Primary antibodies were: anti-human CD3 (2GV6, Ventana), anti-human CD8 (C8/144b, Dako), anti-human CD20 (L26, Dako), anti-human DC-LAMP (1010E1.01, Novus biologicals), anti-human PD-L1 (E1L3N, Cell Signaling Technologies), anti-human CD206 (polyclonal, Abcam), and anti-human HLA Class I (EMR8-5, Abcam).
Histological Quantification
A piece of tumor sample was embedded in paraffin, and tumors and lung tissue included in the study were stained with H&E, and assessed by a lung pathologist for inclusion in the study. For tertiary lymphoid structure grading, adjacent slices were cut and stained for CD20 according to the above immunohistochemistry protocol. Analysis using Halo Software (IndicaLabs) was performed on tumor, excluding normal lung, empty space, and necrotic areas. B cell follicles were identified, and number and area of B cell follicles/mm 2 were quantified. Only B cell follicles larger than 0.0014mm 2 were counted. MHC Class I immune-staining was quantified by the percent of tumor cells expressing the molecule.
TCR Variable Beta Chain Sequencing
Immunosequencing of the CDR3 regions of human TCRb chains was performed using the ImmunoSEQ TM Assay (Adaptive Biotechnologies, Seattle, WA). Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCRb CDR3 region for further analysis as previously described (Carlson et al., 2013; Robins et al., 2012; Robins et al., 2009) Statistical Analyses of TCR-b Sequencing Clonality was defined as 1-Peilou's eveness (Kirsch et al., 2015) and was calculated on productive rearrangements by:
where p i is the proportional abundance of rearrangement i and N is the total number of rearrangements. Clonality values range from 0 to 1 and describe the shape of the frequency distribution: clonality values approaching 0 indicate a very even distribution of frequencies, whereas values approaching 1 indicate an increasingly asymmetric distribution in which a few clones are present at high frequencies. Clonality between experimental groups was compared using a two-tailed Wilcoxon Rank Sum test; correlations between T-cell fraction or clonality and CyTOF data were assessed using Spearman's Rank Correlation after running a ShapiroWilk test for normality. Statistical analyses were performed in R version 3.3.
Tissue Digestion
Complete media was prepared with RPMI (Corning), 10% FBS (Life Technologies), 1% non-essential amino acids (Corning), 1% sodium-pyruvate (Corning), 1% L-glutamine (Corning), 1% penicillin-streptomycin (Life Technologies) and 1% HEPES buffer (Corning). The non-involved lung and tumor tissue remaining after collecting the histological sections were each minced with scissors in separate 6-well plates (Costar) and enzymatically digested in complete media supplemented with 0.225 mg/mL collagenase type IV (Sigma-Aldrich) for 45 minutes at 37 C. The samples were passed through a syringe and a 16-gauge needle to further separate and yield single cell suspensions. The cells were then filtered through a 70 mm cell strainer, washed, lysed in RBC buffer (BioLegend) and refiltered through a 70 mm cell strainer. The cells were resuspended in complete media and counted by hemocytometer.
PBMC Isolation
The PBMCs were collected via a Ficoll-Paque PLUS (GE Healthcare) gradient. PBMCs were washed and resuspended in complete media to create a single cell suspension. Cells were counted with a hemocytometer.
Secreted Soluble Factor Profiling
Single cell suspensions from non-involved lung, tumor, and PBMCs were cultured overnight for secreted soluble factor profiling. From each sample type, 200,000 cells were plated in duplicate into individual wells of a flat-bottom 96-well plate (Corning) in 250mL of complete media and incubated at 37 C overnight. 200mL of supernatant were collected and stored at -80 C until multiplex biomarkers assay was performed.
Measurement of Multiplex Biomarkers
The overnight supernatant collected for the secreted soluble factor profiling was used for the Luminex-200 multiplex biomarker assay, which was performed according to the manufacturer's instructions. Briefly, cell suspension supernatants collected in microcentrifuge tubes were thawed and spun at 12,000 RPM for 10 minutes at 4 C to remove precipitates. Duplicates of 25 ml of each supernatant were analyzed undiluted to determine the concentrations of 41 biomarkers using a Milliplex MAP Human Cytokine/Chemokine 41plex kit (EMD Millipore, Billerica, Massachusetts) on the Luminex-200 multiplex immunoassay system. Data were analyzed using Milliplex Analyst 5.1 software (EMD Millipore, Billerica, Massachusetts). Measurements were corrected for noise by subtracting the average of two technical control wells for each secreted soluble factor.
CyTOF Sample Preparation
Antibodies were either purchased pre-conjugated from Fluidigm (formerly DVS Sciences) or purchased purified and conjugated in-house using MaxPar X8 Polymer Kits (Fluidigm) according to the manufacturer's instructions. For the first cohort of 22 patients (18 with adenocarcinoma), cells from each tissue (blood, non-involved lung, and tumor) were labelled with a unique barcode by incubating with CD45-antibodies conjugated to distinct metal isotopes before pooling. The pooled sample was stained for viability with 5mM cisplatin in PBS (Fluidigm) for 2 minutes at RT. Cells were then washed and split into two equal aliquots. One aliquot was stained with a T-cell focused panel of antibodies (Panel 1, see below) and the other aliquot was stained with a myeloid focused panel of antibodies (Panel 2) for 30 min on ice. Samples were washed, fixed, and permeabilized (eBiosciences) at 4 C overnight before being stained with intracellular antibodies (see below, highlighted). They were washed and incubated in 0.125nM Ir intercalator (Fluidigm) diluted in PBS containing 2% formaldehyde, and stored at 4 C until acquisition. For the second cohort of 10 patients, cells were stained with a mass cytometry panel including cytokines (Panel 3). Cells from each tissue type (blood, non-involved lung, tumor) were split into two fractions for a total of 6 aliquots. Aliquots from each tissue were incubated in 20mg/mL Brefeldin A (Sigma) alone or 20mg/mL Brefeldin A, 1.6mg/mL PMA (Sigma) and 6mg/mL Ionomycin (Sigma) for 4 hours at 37 C. Rhodamine viability stain (Fluidigm) was added for the last 20 minutes of incubation. Cells were washed and stained with cell surface antibodies for 30 minutes on ice, before being fixed and permeabilized (BD Biosciences). Samples were washed and incubated with a unique Pd barcode (Fluidigm) for 30 minutes at RT, washed, then pooled. The pooled sample was stained with intracellular antibodies for 30 minutes on ice, washed, and incubated in 0.125nM Ir intercalator (Fluidigm) diluted in PBS containing 2% formaldehyde and stored at 4 C until acquisition.
CyTOF Data Acquisition
Immediately prior to acquisition, samples were washed once with PBS, once with de-ionized water and then resuspended at a concentration of 1 million cells/ml in deionized water containing a 1/20 dilution of EQ 4 Element Beads (Fluidigm). The samples were acquired on a CyTOF2 (Fluidigm) equipped with a SuperSampler fluidics system (Victorian Airships) at an event rate of <500 events/second. After acquisition, the data were normalized using bead-based normalization in the CyTOF software. Barcodes were deconvoluted using the Fluidigm debarcoding software, or by manual Boolean gating in the case of CD45-barcoded samples. The data were gated to exclude residual normalization beads, debris, dead cells and doublets, leaving DNA+CD45+Cisplatin low events for subsequent clustering and high dimensional analyses.
CyTOF Clustering: viSNE and Phenograph CyTOF data was visualized using viSNE (Amir et al., 2013) , a dimensionality reduction method which uses the Barnes-Hut acceleration of the t-SNE algorithm (van der Maaten, 2014; van der Maaten and Hinton, 2008) . viSNE was implemented using either the Rtsne R package (Krijthe, 2015) or Cytobank (Chen and Kotecha, 2014) . viSNE plots were generated separately for each patient incorporating all tissues. Single cell data was clustered within and across samples using Phenograph (Levine et al., 2015) , a clustering method based on the Louvain community detection algorithm (Blondel et al., 2008) . The graph for Louvain was built using the FNN R package (Blondel et al., 2008) , and the method was implemented using the igraph package (Csardi and Nepusz, 2006) . In brief, Louvain communities of single cells were generated for each patient based on marker expression levels and independent of the sample source (blood, noninvolved lung, or tumor). To detect common cell populations across patients, the mean protein expression levels among each Louvain community were then used to form larger Louvain communities (called metaclusters).
For the first patient cohort, 3 separate Phenograph analyses were performed using (1) CD3+ cells and Panel 1, (2) CD3-cells and Panel 1, and (3) CD3-cells and Panel 2 (Table S2) . One patient was excluded from analysis of NK cells from Phenograph analysis (3) due to faulty antibody staining. The use of Phenograph analysis (2) was limited to the analysis of NK cells in Figures 3B and 3C , and B cells in Figure S1C . For the second cohort, Phenograph was run on CD45+ cells using Panel 3. To identify the major immune lineages, cell counts for the metacluster populations comprising lineages were manually added up across 18 patients (Panel 2) or 10 patients (Panel 3). Absolute numbers were assessed from second cohort (Panel 3).
CyTOF Statistical Analysis
Heatmaps of normalized marker expression, relative marker expression, and relative difference of population frequency were generated by GENE-E or Morpheus from the Broad Institute (https://www.broadinstitute.org/cancer/software/morpheus/). Paired tissue analyses were performed on the frequency of metaclusters and major lineages by performing paired T-tests using GraphPad Prism across tissues (*p<0.05, **p<0.01 and ***p<0.001). Correlation analyses between population frequencies and average normalized expression of protein markers in metaclusters were performed by computing Spearman's rank-based correlation coefficient in GraphPad Prism.
Single-Cell Sorting
Over 700 cells were extracted from non-involved lung and over 1100 cells extracted from the tumor lesion of a pathological stage IA lung adenocarcinoma patient, were single-cell sorted according to the gating strategy shown in Data S2B into 384-well cell capture plates containing 2 mL of lysis solution and barcoded poly(T) reverse-transcription (RT) primers for single-cell RNA-seq. Barcoded single cell capture plates were prepared with a Bravo automated liquid handling platform (Agilent) as described previously (Jaitin et al., 2014) . Four empty wells were kept in each 384-well plate as a no-cell control during data analysis. Immediately after sorting, each plate was spun down to ensure cell immersion into the lysis solution, snap frozen on dry ice, and stored at -80 C until processed.
Massively Parallel Single Cell RNA-Seq Single-cell libraries were prepared as previously described (Jaitin et al., 2014) . Briefly, mRNA from cells sorted into massively parallel single cell RNA-Seq (MARS-Seq) capture plates was barcoded and converted into cDNA and pooled using an automated pipeline. The pooled sample was then linearly amplified by T7 in-vitro transcription. The resulting RNA was fragmented and converted into a sequencing ready library by tagging the samples with pool barcodes and Illumina adaptor sequences during ligation, followed by reverse transcription and PCR. Each pool of cells was tested for library quality and concentration was assessed as described earlier (Jaitin et al., 2014) . All RNA-seq libraries (pooled at equimolar concentration) were sequenced using Illumina sequencers at an average sequencing depth of $40,000 reads per cell for RNA-seq. RNA-seq reads were aligned using hisat 0.1.5 and assigned to exons defined by a reference set obtained from the UCSC genome browser. We used statistics on empty-well spurious unique molecular identifier (UMI) detection to ensure that the batches we used for analysis show a low level of cross-single-cell contamination.
Single-Cell RNA-seq Clustering Analysis MARS-seq reads were processed as previously described (Paul et al., 2015) . In brief, we implemented a multiplicative probabilistic model that represented the probability of sampling UMIs for each gene as a function of the cell's cluster and batch. We then inferred cluster and batch parameters using an expectation maximization (EM)-like procedure using non-linear optimization of the batch and cluster parameters' likelihoods in iterations. After cells and genes with low expression levels were excluded, 1473 remaining cells were grouped into 15 clusters. Of these, 8 clusters demonstrated high expression of genes specific to mononuclear phagocytes and thus were selected for a final re-clustering analysis, producing 10 sub-clusters. These clusters were then identified as distinct immune cell types based on literature review of highly and differentially expressed genes. For Figures 5B, 6A , and 6B, transcript expression profiles of clusters 5 and 6 were combined by weighted average using the respective frequencies of each cluster among mononuclear phagocytes. Scatter plots and lists of differentially expressed genes between clusters were generated using the 50% most highly expressed transcripts among those detected after averaging expression profiles of compared clusters.
RNA Isolation for Bulk RNA-seq A minimum of 5000 cells were sorted according to the gating strategy in Data S2A in 200ul of Lysis/Binding Buffer (Life technologies), lysed for 5 min and frozen at -8 C. Cell lysates were thawed and messenger RNA was captured with 12 ul of Dynabeads oligo(dT) (Life technologies), and washed according to manufacture guidelines. Purified messenger RNA was eluted at 70C with 10ul of 10mM Tris-Cl pH 7.5 and stored at -80 C.
Bulk RNA-seq We used the MARS-seq protocol (Jaitin et al., 2014) , developed for single cell RNA-seq and discussed above, to produce RNA-seq libraries for bulk RNA-seq. One step of linear amplification of the initial mRNA pool was performed, followed by a library construction. A minimum of 2 replicate libraries were prepared for each sorted population. Libraries were sequenced using Illumina sequencers. RNA-seq reads were aligned as above, and expression levels were calculated and normalized for each sample to the total number of identified UMIs. Differential expression analysis was performed using the R-package Limma (Ritchie et al., 2015) . Heatmaps were generated with genes differentially expressed with unadjusted p-value<0.01 and greater than 2-fold differential expression.
TCGA Analysis
Tumor RNAseq counts data from 515 lung adenocarcinoma patients were downloaded from Genomic Data Commons Portal https:// gdc-portal.nci.nih.gov/. Normalized log-transformed expression was computed as log2(CPM) (counts per million reads) using the TMM normalization (Robinson and Oshlack, 2010) . For each patient, expression levels of the genes differentially expressed between tumor macrophages and lung macrophages according to the scRNAseq experiment ( Figure 4A ) were centered so that the mean across all samples was zero. Consensus expression of tumor macrophage and lung macrophage genes for each sample were computed as the median across all the signature genes. Concordance index was calculated as the ratio of the consensus expression of tumor macrophage signature genes to the consensus expression of the lung macrophage signature genes. Patients were divided into the top and bottom 50th percentiles of the concordance index. Survival analysis was performed in R.
QUANTIFICATION AND STATISTICAL ANALYSIS
Several data types, such as CyTOF meta-clusters, secreted soluble factor concentration, or normalized transcript counts, were stratified. Bar graphs show mean ± SEM. Student's paired t test, Spearman's rank-based correlation coefficient, Fisher's exact test, and the Long-rank test were used to determine significance. P-values are indicated on plots and in figure legends. (* p < 0.05, ** p < 0.01, *** p < 0.001).
DATA AND SOFTWARE AVAILABILITY
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through accession number GEO: GSE97168 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97168). (legend continued on next page)
